Barclays PLC Raises Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Barclays PLC grew its position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 119.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,036 shares of the medical equipment provider's stock after acquiring an additional 39,182 shares during the quarter. Barclays PLC owned about 0.16% of AxoGen worth $1,010,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Quest Partners LLC raised its position in AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 2,076 shares during the last quarter. nVerses Capital LLC bought a new position in shares of AxoGen during the third quarter valued at about $56,000. Oppenheimer & Co. Inc. purchased a new position in AxoGen during the third quarter worth about $156,000. Quantbot Technologies LP bought a new stake in AxoGen in the 3rd quarter worth about $165,000. Finally, BNP Paribas Financial Markets increased its stake in AxoGen by 238.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider's stock valued at $172,000 after buying an additional 8,656 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

AxoGen Stock Performance

AXGN stock traded up $0.47 during mid-day trading on Wednesday, hitting $18.71. The company had a trading volume of 561,096 shares, compared to its average volume of 729,392. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market cap of $823.39 million, a PE ratio of -58.47 and a beta of 1.01. AxoGen, Inc. has a 12 month low of $5.55 and a 12 month high of $18.75. The stock's fifty day moving average price is $14.80 and its two-hundred day moving average price is $12.88.

Analysts Set New Price Targets

Separately, StockNews.com raised AxoGen from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $15.00.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.